Development of an Outpatient Oncology Symptom Management Clinic

Kyra Whitmer, PhD, RN, Jane Pruemer, PharmD, BCOP, Cheryl Wilhelm, RN, OCN®, Linda McCaig, RN, ACRN, and Jennifer D.B. Hester, DNP, AOCNS®, ACHPN

The Symptom Management Clinic (SMC) at University Hospital in Cincinnati, OH, was established to meet identified needs of patients with cancer seen in an outpatient setting. The initial step in the formation of the SMC consisted of the development of a business plan and the presentation of that business plan to the hospital administration. The development of clinic procedures using the creation of a guideline for pain management as an example is presented, as are medication reconciliation and patient teaching. Implications for clinical practice include the essential nature of collaborative relationships among medical oncologists, nursing, pharmacy, and administrative staff members. Interdisciplinary collaboration among the staff of the SMC facilitated referral to appropriate services within the institution and community.

At a Glance

- Collaborative relationships among oncologists, nurses, and pharmacy and administrative staff led to the establishment of the Symptom Management Clinic (SMC) for patients with cancer treated in an outpatient setting.
- Staffing and monetary goals were set at SMC’s inception and met in the allotted time period.
- A focus of the SMC treatment plan was medication reconciliation, which improves patient safety by reducing medication discrepancies and possible drug-drug interactions.

Cancer Society. Breast, melanoma, and lung are the three most frequent cancers diagnosed and treated at BCC. Multidisciplinary clinics staffed by surgical oncologists, medical oncologists, radiation therapists, radiologists, oncology nurses, and clinical pharmacists collaborate to evaluate and treat patients. Innovative clinical research is supported by active protocols sponsored by cooperative programs through the National Cancer Institute as well as investigator-initiated studies and studies funded by private pharmaceutical companies.

Kyra Whitmer, PhD, RN, is an emeritus associate professor and nurse researcher in the College of Nursing, and Jane Pruemer, PharmD, BCOP, is a professor in the James L. Winkle College of Pharmacy, both at the University of Cincinnati; Cheryl Wilhelm, RN, OCN®, and Linda McCaig, RN, ACRN, both are RNs at University Hospital; and Jennifer D.B. Hester, DNP, AOCNS®, ACHPN, is a palliative care clinical nurse specialist at Christ Hospital, all in Cincinnati, OH. The authors take full responsibility for the content of the article. The authors did not receive honoraria for this work. The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias. No financial relationships relevant to the content of this article have been disclosed by the authors, planners, independent peer reviewers, or editorial staff. (First submission June 2010. Revision submitted September 2010. Accepted for publication September 9, 2010.)

Digital Object Identifier:10.1188/11.CJON.175-179

Downloaded on 08-17-2023. Single-user license only. Copyright 2023 by the Oncology Nursing Society. For permission to post online, reprint, adapt, or reuse, please email pubpermissions@ons.org. ONS reserves all rights.